PTCL, NOS: An update on classification, risk-stratification, and treatment

Jonathan Weiss; John Reneau; Ryan A Wilcox

doi:10.3389/fonc.2023.1101441

PTCL, NOS: An update on classification, risk-stratification, and treatment

Front Oncol. 2023 Feb 9:13:1101441. doi: 10.3389/fonc.2023.1101441. eCollection 2023.

Authors

Jonathan Weiss¹, John Reneau², Ryan A Wilcox¹

Affiliations

¹ Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States.
² Department of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

Abstract

The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the most common PTCL in North America remains "not otherwise specified (NOS)" and is an unmet need. However, improved understanding of the genetic landscape and ontogeny for the PTCL subtypes currently classified as PTCL, NOS have been realized, and have significant therapeutic implications, which will be reviewed here.

Keywords: GATA-3; PTCL; PTCL-NOS; classification; risk stratification; treatment.

Publication types

Review

Abstract

Publication types

Grants and funding